The KEAP1-NRF2 pathway: Targets for therapy and role in cancer

被引:89
|
作者
Adinolfi, Simone [1 ]
Patinen, Tommi [1 ]
Deen, Ashik Jawahar [1 ]
Pitkänen, Sini
Härkönen, Jouni [2 ]
Kansanen, Emilia [1 ,3 ]
Küblbeck, Jenni [1 ]
Levonen, Anna-Liisa [1 ]
机构
[1] Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, FI-70210 Kuopio, Finland
[2] Hosp Nova Cent Finland, Dept Pathol, Jyvaskyla 40620, Finland
[3] Kuopio Univ Hosp, Sci Serv Ctr, Kuopio, Finland
来源
REDOX BIOLOGY | 2023年 / 63卷
关键词
NRF2; KEAP1; Cancer; Gene regulation; TRANSCRIPTION FACTOR NRF2; LUNG-CANCER; OXIDATIVE STRESS; ANTIOXIDANT RESPONSE; STRUCTURAL BASIS; GENE; PROTEIN; ACTIVATION; SUBSTRATE; DEGRADATION;
D O I
10.1016/j.redox.2023.102726
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The KEAP1-NRF2 pathway is the key regulator of cellular defense against both extrinsic and intrinsic oxidative and electrophilic stimuli. Since its discovery in the 1990s, its seminal role in various disease pathologies has become well appreciated, motivating research to elucidate the intricacies of NRF2 signaling and its downstream effects to identify novel targets for therapy. In this graphical review, we present an updated overview of the KEAP1-NRF2 signaling, focusing on the progress made within the past ten years. Specifically, we highlight the advances made in understanding the mechanism of activation of NRF2, resulting in novel discoveries in its therapeutic targeting. Furthermore, we will summarize new findings in the rapidly expanding field of NRF2 in cancer, with important implications for its diagnostics and treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis
    Abu-Alainin, Wafa
    Gana, Thompson
    Liloglou, Triantafillos
    Olayanju, Adedamola
    Barrera, Lawrence N.
    Ferguson, Robert
    Campbell, Fiona
    Andrews, Timothy
    Goldring, Christopher
    Kitteringham, Neil
    Park, Brian K.
    Nedjadi, Taoufik
    Schmid, Michael C.
    Slupsky, Joseph R.
    Greenhalf, William
    Neoptolemos, John P.
    Costello, Eithne
    JOURNAL OF PATHOLOGY, 2016, 238 (03): : 423 - 433
  • [32] Applications of the Keap1-Nrf2 system for gene and cell therapy
    Kanninen, Katja M.
    Pomeshchik, Yuriy
    Leinonen, Hanna
    Malm, Tarja
    Koistinaho, Jari
    Levonen, Anna-Liisa
    FREE RADICAL BIOLOGY AND MEDICINE, 2015, 88 : 350 - 361
  • [33] Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma
    Clerici, Sara
    Boletta, Alessandra
    CANCERS, 2020, 12 (11) : 1 - 25
  • [34] The Role of KEAP1-NRF2 System in Atopic Dermatitis and Psoriasis
    Ogawa, Tatsuya
    Ishitsuka, Yosuke
    ANTIOXIDANTS, 2022, 11 (07)
  • [35] Harnessing the Noncanonical Keap1-Nrf2 Pathway for Human Cytomegalovirus Control
    Ghosh, Ayan K.
    Su, Yu-Pin
    Forman, Michael
    Keyes, Robert F.
    Smith, Brian C.
    Hu, Xin
    Ferrer, Marc
    Arav-Boger, Ravit
    JOURNAL OF VIROLOGY, 2023, 97 (04)
  • [36] Proteomic and Functional Analyses of Keap1-Nrf2 Pathway in Skeletal Muscle
    Gao, Lie
    Kumar, Vikas
    Hackfort, Bryan
    Rudebush, Tara L.
    Yu, Li
    Schultz, Harold D.
    Zucker, Irving H.
    FASEB JOURNAL, 2019, 33
  • [37] Keap1-Nrf2 Signaling: A Target for Cancer Prevention by Sulforaphane
    Kensler, Thomas W.
    Egner, Patricia A.
    Agyeman, Abena S.
    Visvanathan, Kala
    Groopman, John D.
    Chen, Jian-Guo
    Chen, Tao-Yang
    Fahey, Jed W.
    Talalay, Paul
    NATURAL PRODUCTS IN CANCER PREVENTION AND THERAPY, 2013, 329 : 163 - 177
  • [38] The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment
    Taguchi, Keiko
    Yamamoto, Masayuki
    CANCERS, 2021, 13 (01) : 1 - 21
  • [39] Somatic Mutations in KEAP1-NRF2 Complex in Breast Cancer
    Almeida, Micaela
    Ferreira, Catarina L.
    Tome, Rosa Maria
    Fonseca-Moutinho, Jose
    Polonia, Antonio
    Ramalhinho, Ana Cristina
    Breitenfeld, Luiza
    CANCERS, 2024, 16 (13)
  • [40] Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane
    Kensler, Thomas W.
    ANTI-CANCER DRUGS, 2015, 26 : E3 - E4